Compare RFIL & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RFIL | PYXS |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 71.6M |
| IPO Year | N/A | 2021 |
| Metric | RFIL | PYXS |
|---|---|---|
| Price | $11.25 | $1.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $9.25 | $6.75 |
| AVG Volume (30 Days) | 363.3K | ★ 1.2M |
| Earning Date | 03-16-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $80,586,000.00 | $2,820,000.00 |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $10.30 | N/A |
| P/E Ratio | $1,379.94 | ★ N/A |
| Revenue Growth | ★ 24.25 | N/A |
| 52 Week Low | $3.39 | $0.83 |
| 52 Week High | $12.24 | $5.55 |
| Indicator | RFIL | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company operates through two segments: RF Connector and Cable Assembly, which consists of the Connector and Cable Assembly Division, and Custom Cabling Manufacturing and Assembly, which consists of its subsidiaries. Connector segment designs, manufactures, markets and distributes a broad range of RF connector, adapter, coupler, divider, and cable products etc. The Custom Cabling segment custom copper and fiber cable assemblies etc. The company operates in Canada, Italy, China, USA, UK.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.